CORT Nasdaq Pharmaceuticals Financials FY2016βFY2025
Corcept Therapeutics had $761M of revenue in fiscal 2025, up 12.8% on the year before. Over five years, revenue changed +16.6% a year on average.
Hi! I read Corcept Therapeuticsβs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+12.8%
Yes. Sales grew 12.8% last year.
Does it make a profit?
13.1%
Yes. It keeps 13.1% of every sale as profit.
Does profit turn into cash?
18.6%
Yes. 18.6% of sales ends up as free cash.
Is debt under control?
Net cash
Yes. It has more cash than debt.
How healthy are the accounts?
3 / 9
Weak. It passes 3 of 9 health tests.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
KIRA Β· Corcept Therapeutics had $761M of revenue in fiscal 2025, up 12.8% on the year before. Over five years, revenue changed +16.6% a year on average. Its operating margin was 5.9%, down 14.4Β pts: of every 100 in sales, about 6 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Corcept Therapeutics made $99.7M of net profit in fiscal 2025. From fiscal 2016 to 2025, diluted EPS grew 31.4% a year.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was $142M in fiscal 2025, 18.6% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
KIRA Β· Corcept Therapeutics returned $173M to shareholders in fiscal 2025, 122% of free cash flow. The diluted share count rose 5.7%.
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· In the last 12 months, insiders bought $3.3M and sold $101M of shares on the open market.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$3.3M
1 insider
Sold, 12 months
$101M
10 insiders
Of sales under plans
93%
$94.2M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Oct 15, 2026 | James N WilsonDirector | Sold plan | 10,000 | $114.81 | $1.1M | Form 4 |
| Oct 2, 2026 | Sean MaduckSee Remarks | Sold plan | 24,587 | $116.28 | $2.9M | Form 4 |
| Oct 2, 2026 | Joseph Douglas LyonSee Remarks | Sold plan | 9,190 | $116.13 | $1.1M | Form 4 |
| Oct 2, 2026 | Roberto Wandenkolk VieiraPresident, Oncology | Sold plan | 8,333 | $116.10 | $1.0M | Form 4 |
| Oct 1, 2026 | Sean MaduckSee Remarks | Sold plan | 413 | $115.54 | $0.0M | Form 4 |
| Oct 1, 2026 | Joseph Douglas LyonSee Remarks | Sold plan | 810 | $115.40 | $0.1M | Form 4 |
| Sep 16, 2026 | Roberto Wandenkolk VieiraPresident, Oncology | Sold plan | 296 | $100.82 | $0.0M | Form 4 |
| Sep 15, 2026 | James N WilsonDirector | Sold plan | 10,000 | $110.69 | $1.1M | Form 4 |
| Sep 14, 2026 | Joseph Douglas LyonSee Remarks | Sold plan | 10,000 | $113.50 | $1.1M | Form 4 |
| Sep 2, 2026 | Roberto Wandenkolk VieiraPresident, Oncology | Sold plan | 58,333 | $110.76 | $6.5M | Form 4 |
| Sep 1, 2026 | Sean MaduckSee Remarks | Sold plan | 25,000 | $114.43 | $2.9M | Form 4 |
| Aug 26, 2026 | Kimberly ParkDirector | Sold | 26,685 | $122.55 | $3.3M | Form 4 |
| Aug 25, 2026 | Sean MaduckSee Remarks | Sold plan | 30,955 | $125.58 | $3.9M | Form 4 |
| Aug 18, 2026 | David L MahoneyDirector | Sold plan | 103,606 | $118.25 | $12.3M | Form 4 |
| Aug 17, 2026 | Gary Charles RobbChief Business Officer | Sold | 10,000 | $116.26 | $1.2M | Form 4 |
| Aug 14, 2026 | Sean MaduckSee Remarks | Sold plan | 3,664 | $114.49 | $0.4M | Form 4 |
| Aug 14, 2026 | James N WilsonDirector | Sold plan | 10,000 | $111.42 | $1.1M | Form 4 |
| Aug 10, 2026 | Sean MaduckSee Remarks | Sold plan | 1,031 | $114.52 | $0.1M | Form 4 |
| Aug 10, 2026 | William GuyerChief Development Officer | Sold plan | 16,300 | $113.43 | $1.8M | Form 4 |
| Aug 4, 2026 | William GuyerChief Development Officer | Sold plan | 3,700 | $113.12 | $0.4M | Form 4 |
| Aug 3, 2026 | Joseph Douglas LyonSee Remarks | Sold | 1,540 | $114.16 | $0.2M | Form 4 |
| Aug 3, 2026 | Sean MaduckSee Remarks | Sold plan | 20,305 | $114.70 | $2.3M | Form 4 |
| Jul 30, 2026 | Atabak MokariChief Financial Officer | Sold plan | 80,000 | $114.72 | $9.2M | Form 4 |
| Jul 15, 2026 | Atabak MokariChief Financial Officer | Sold plan | 40,000 | $87.71 | $3.5M | Form 4 |
| Jul 15, 2026 | James N WilsonDirector | Sold plan | 10,000 | $88.30 | $0.9M | Form 4 |
| Jul 7, 2026 | William GuyerChief Development Officer | Sold plan | 20,000 | $93.13 | $1.9M | Form 4 |
| Jul 1, 2026 | Sean MaduckSee Remarks | Sold plan | 25,000 | $88.35 | $2.2M | Form 4 |
| Jun 17, 2026 | David L MahoneyDirector | Sold | 20,000 | $84.53 | $1.7M | Form 4 |
| Jun 16, 2026 | James N WilsonDirector | Sold plan | 10,000 | $83.20 | $0.8M | Form 4 |
| Jun 15, 2026 | Atabak MokariChief Financial Officer | Sold plan | 40,000 | $81.15 | $3.2M | Form 4 |
| Jun 2, 2026 | William GuyerChief Development Officer | Sold plan | 20,000 | $70.60 | $1.4M | Form 4 |
| Jun 1, 2026 | Atabak MokariChief Financial Officer | Sold plan | 40,000 | $70.00 | $2.8M | Form 4 |
| Jun 1, 2026 | Sean MaduckSee Remarks | Sold plan | 25,000 | $70.21 | $1.8M | Form 4 |
| Jun 1, 2026 | Joseph K BelanoffChief Executive Officer, Director | Sold plan | 12,837 | $69.74 | $0.9M | Form 4 |
| May 27, 2026 | Joseph Douglas LyonSee Remarks | Sold | 5,000 | $65.00 | $0.3M | Form 4 |
| May 27, 2026 | Sean MaduckSee Remarks | Sold plan | 75,000 | $65.59 | $4.9M | Form 4 |
| May 5, 2026 | William GuyerChief Development Officer | Sold plan | 20,000 | $51.83 | $1.0M | Form 4 |
| May 1, 2026 | Joseph K BelanoffChief Executive Officer, Director | Sold plan | 40,000 | $50.10 | $2.0M | Form 4 |
| Apr 7, 2026 | William GuyerChief Development Officer | Sold plan | 20,000 | $40.97 | $0.8M | Form 4 |
| Mar 25, 2026 | Joseph K BelanoffChief Executive Officer, Director | Sold plan | 26,198 | $50.07 | $1.3M | Form 4 |
| Mar 20, 2026 | William GuyerChief Development Officer | Sold plan | 11,767 | $36.01 | $0.4M | Form 4 |
| Mar 17, 2026 | G Leonard Baker JrDirector | Bought | 100,000 | $33.14 | $3.3M | Form 4 |
| Mar 4, 2026 | William GuyerChief Development Officer | Sold plan | 8,233 | $35.99 | $0.3M | Form 4 |
| Feb 3, 2026 | William GuyerChief Development Officer | Sold plan | 20,000 | $40.87 | $0.8M | Form 4 |
| Jan 6, 2026 | William GuyerChief Development Officer | Sold plan | 20,000 | $35.18 | $0.7M | Form 4 |
| Dec 2, 2025 | William GuyerChief Development Officer | Sold plan | 20,000 | $80.08 | $1.6M | Form 4 |
| Dec 1, 2025 | Joseph Douglas LyonSee Remarks | Sold plan | 5,000 | $79.53 | $0.4M | Form 4 |
| Dec 1, 2025 | Joseph K BelanoffChief Executive Officer, Director | Sold plan | 40,000 | $79.77 | $3.2M | Form 4 |
| Dec 1, 2025 | Sean MaduckSee Remarks | Sold plan | 20,000 | $79.52 | $1.6M | Form 4 |
| Nov 25, 2025 | William GuyerChief Development Officer | Sold | 4,500 | $80.90 | $0.4M | Form 4 |
| Nov 5, 2025 | Joseph K BelanoffChief Executive Officer, Director | Sold plan | 28,782 | $74.78 | $2.2M | Form 4 |
| Nov 5, 2025 | William GuyerChief Development Officer | Sold plan | 20,000 | $75.36 | $1.5M | Form 4 |
| Nov 3, 2025 | Joseph K BelanoffChief Executive Officer, Director | Sold plan | 11,218 | $74.08 | $0.8M | Form 4 |
| Nov 3, 2025 | Sean MaduckSee Remarks | Sold plan | 20,000 | $73.99 | $1.5M | Form 4 |
| Nov 3, 2025 | Joseph Douglas LyonSee Remarks | Sold plan | 5,000 | $73.65 | $0.4M | Form 4 |
| Oct 10, 2025 | Daniel N Swisher JRDirector | Sold plan | 2,200 | $87.54 | $0.2M | Form 4 |
| Oct 7, 2025 | William GuyerChief Development Officer | Sold plan | 20,000 | $89.94 | $1.8M | Form 4 |
| Oct 1, 2025 | Joseph K BelanoffChief Executive Officer, Director | Sold plan | 40,000 | $85.08 | $3.4M | Form 4 |
| Oct 1, 2025 | Joseph Douglas LyonSee Remarks | Sold plan | 5,000 | $84.75 | $0.4M | Form 4 |
| Oct 1, 2025 | Sean MaduckSee Remarks | Sold plan | 20,000 | $85.07 | $1.7M | Form 4 |
Can it carry its debts, and how well does it use its money?
KIRA Β· Corcept Therapeutics has $372M more cash than debt.
Cash, debt and the ratios that show how comfortably Corcept Therapeutics can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $224M | $432M | $368M | $383M | $372M |
| Debt incl. finance leases | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Net debt / EBITDA | β1.8x | β3.8x | β3.4x | β2.8x | β8.1x |
| Debt / equity | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x |
| Current ratio | 5.6x | 6.9x | 4.4x | 3.4x | 2.9x |
| Quick ratio | 5.5x | 6.8x | 4.3x | 3.3x | 2.9x |
| Total assets | $424M | $583M | $622M | $841M | $837M |
| Total liabilities | $47.9M | $81.6M | $115M | $161M | $189M |
| Shareholders' equity | $376M | $502M | $507M | $680M | $648M |
| Net debt (β = net cash) | β$224M | β$432M | β$368M | β$383M | β$372M |
KIRA Β· Its return on capital was 15.7%: every 100 invested in the business earned about 16 in a year.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Corcept Therapeutics passes 3 of 9 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | β | β | β |
| Cash from operations is positive | β | β | β |
| Return on assets rose | β | β | β |
| Cash from operations exceeds net income | β | β | β |
| Debt fell relative to assets | β | β | β |
| Current ratio rose | β | β | β |
| Share count didn't rise | β | β | β |
| Gross margin rose | β | β | β |
| Revenue rose relative to assets | β | β | β |
| F-score | 4 / 9 | 5 / 9 | 3 / 9 |
| Accruals ratio | β3.4% | β7.8% | β5.1% |
| Altman Z'' | 11.64 | 10.22 | 8.97 |
What does the share cost, and how does it compare?
KIRA Β· At $85.86 a share, the company is worth $10.2B.
Change the assumptions and see what they imply per share. These are models, not forecasts or price targets β the answer depends entirely on what you put in.
In plain words: Move the sliders to try your own guesses about growth. The result is what one share would be worth if those guesses came true. Different guesses give very different answers.
Value per share
β
Adds net cash of $372M and divides by 120.0M diluted shares. Ten years of cash flows plus a terminal value, discounted to today.
Value per share
β
Reference multiples: today β Β· peers 15.3x Β· sector 28.1x.
KIRA Β· Corcept Therapeutics grew sales faster than 2 of its 4 similar companies.
Each companyβs latest fiscal year. Fiscal years end in different months, so periods donβt line up exactly.
In plain words: The same numbers for similar companies, so you can tell whether a figure is high or low for this kind of business.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score | |
|---|---|---|---|---|---|---|---|---|
| Corcept Therapeutics CORT | $10.2B | 12.8% | 5.9% | 18.6% | 15.7% | β | 3 | |
| Collegium Pharmaceutical COLL | $746M | 23.6% | 23.0% | 42.0% | 53.4% | 18.5x | 6 | Compare β |
| Amphstar Pharmaceuticals AMPH | $1.1B | β1.7% | 19.5% | 16.8% | 9.9% | 14.9x | 6 | Compare β |
| ANI Pharmaceuticals ANIP | $1.6B | 43.8% | 12.6% | 19.4% | 15.9% | 15.7x | 6 | Compare β |
| Acadia Pharmaceuticals ACAD | $3.4B | 11.9% | 9.8% | 9.8% | β | 8.8x | β | Compare β |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $81.3M | $159M | $251M | $307M | $354M | $366M | $402M | $482M | $675M | $761M |
| Gross profit | $79.3M | $156M | $246M | $301M | $348M | $361M | $397M | $476M | $664M | $748M |
| Research and development | $23.8M | $40.4M | $75.2M | $89.0M | $115M | $114M | $131M | $184M | $247M | $255M |
| Operating income | $10.2M | $52.9M | $89.5M | $112M | $128M | $125M | $113M | $107M | $137M | $44.8M |
| Interest expense | $2.0M | β | β | β | β | β | β | β | β | β |
| Pretax income | $8.1M | $52.8M | $92.2M | $117M | $132M | $125M | $116M | $125M | $162M | $66.5M |
| Income tax | $0.0M | β$76.3M | $16.7M | $22.5M | $25.6M | $12.5M | $14.8M | $18.4M | $20.3M | β$33.2M |
| Net income | $8.1M | $129M | $75.4M | $94.2M | $106M | $113M | $101M | $106M | $141M | $99.7M |
| Diluted EPS | $0.07 | $1.04 | $0.60 | $0.77 | $0.85 | $0.89 | $0.87 | $0.94 | $1.23 | $0.82 |
| Diluted shares | 0.12B | 0.12B | 0.13B | 0.12B | 0.12B | 0.13B | 0.12B | 0.11B | 0.11B | 0.12B |
| Cash flow | ||||||||||
| Cash from operations | $18.4M | $60.9M | $116M | $136M | $152M | $168M | $120M | $127M | $198M | $142M |
| Capital expenditure | $0.2M | $0.4M | $0.3M | $1.1M | $1.2M | $0.5M | $0.4M | $0.1M | $2.2M | $0.2M |
| Free cash flow | $18.2M | $60.5M | $115M | $135M | $151M | $167M | $120M | $127M | $196M | $142M |
| Depreciation and amortization | $0.1M | $0.1M | $0.2M | $0.7M | $0.5M | $1.1M | $1.3M | $1.0M | $0.8M | $1.1M |
| Stock-based compensation | $7.1M | $13.4M | $23.7M | $29.3M | $33.5M | $42.9M | $42.4M | $48.9M | $61.4M | $84.5M |
| Acquisitions | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Share buybacks | $0.0M | $0.0M | $23.7M | $31.0M | $9.9M | $0.0M | $0.0M | $0.0M | $15.7M | $173M |
| Dividends paid | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Dividends and buybacks | $0.0M | $0.0M | $23.7M | $31.0M | $10.0M | $0.0M | $0.0M | $0.0M | $15.7M | $173M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $51.5M | $88.7M | $207M | $276M | $441M | $224M | $432M | $368M | $383M | $372M |
| Total debt | $14.7M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Finance lease liabilities | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Current assets | $65.7M | $124M | $237M | $307M | $479M | $267M | $499M | $459M | $472M | $486M |
| Current liabilities | $27.4M | $29.6M | $35.6M | $38.8M | $47.5M | $47.5M | $72.5M | $105M | $141M | $166M |
| Inventory | $2.3M | $4.6M | $4.7M | $5.4M | $4.9M | $5.0M | $6.1M | $7.7M | $12.4M | $12.9M |
| Property and equipment, net | $0.2M | $0.5M | $0.7M | $1.1M | $1.7M | $1.0M | $0.6M | $0.2M | $2.7M | $1.9M |
| Total assets | $68.8M | $221M | $312M | $412M | $572M | $424M | $583M | $622M | $841M | $837M |
| Total liabilities | $27.4M | $29.6M | $35.8M | $41.1M | $48.4M | $47.9M | $81.6M | $115M | $161M | $189M |
| Shareholders' equity | $41.4M | $191M | $276M | $371M | $523M | $376M | $502M | $507M | $680M | $648M |
| Margins | ||||||||||
| Gross margin | 97.5% | 97.8% | 97.9% | 98.2% | 98.4% | 98.6% | 98.7% | 98.7% | 98.4% | 98.3% |
| Operating margin | 12.5% | 33.2% | 35.6% | 36.4% | 36.2% | 34.0% | 28.0% | 22.2% | 20.3% | 5.9% |
| EBITDA margin | 12.6% | 33.3% | 35.7% | 36.6% | 36.4% | 34.3% | 28.3% | 22.5% | 20.4% | 6.0% |
| Net margin | 10.0% | 81.1% | 30.0% | 30.7% | 30.0% | 30.7% | 25.2% | 22.0% | 20.9% | 13.1% |
| FCF margin | 22.4% | 38.0% | 45.9% | 44.1% | 42.6% | 45.8% | 29.8% | 26.2% | 29.1% | 18.6% |
| Returns | ||||||||||
| Return on capital | β | 99.0% | 85.5% | 109.6% | 116.1% | 95.4% | 88.4% | 87.6% | 55.1% | 15.7% |
| Return on capital employed | 28.1% | 45.5% | 38.3% | 34.4% | 28.6% | 27.7% | 25.4% | 20.9% | 22.5% | 6.5% |
| Return on equity | 27.2% | 111.2% | 32.3% | 29.1% | 23.7% | 25.0% | 23.1% | 21.1% | 23.8% | 15.0% |
| Return on assets | 13.5% | 89.3% | 28.3% | 26.0% | 21.6% | 22.6% | 20.1% | 17.6% | 19.3% | 11.9% |
| Growth | ||||||||||
| Revenue growth | 61.7% | 95.8% | 57.8% | 22.0% | 15.5% | 3.4% | 9.8% | 20.0% | 39.9% | 12.8% |
| Net income growth | β | 1,486.3% | β41.6% | 24.9% | 12.6% | 6.1% | β9.9% | 4.7% | 33.0% | β29.4% |
| EPS growth | β | 1,385.7% | β42.3% | 28.3% | 10.4% | 4.7% | β2.3% | 8.1% | 30.9% | β33.3% |
| FCF growth | 484.6% | 232.6% | 90.6% | 17.0% | 11.6% | 11.1% | β28.4% | 5.5% | 55.0% | β27.7% |
| Share count change | 8.7% | 7.2% | 1.8% | β3.3% | 1.3% | 1.4% | β7.9% | β3.6% | 1.6% | 5.7% |
| Financial health | ||||||||||
| Net debt / EBITDA | β3.6x | β1.7x | β2.3x | β2.5x | β3.4x | β1.8x | β3.8x | β3.4x | β2.8x | β8.1x |
| Debt / equity | 0.4x | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x |
| Interest coverage | 5.0x | β | β | β | β | β | β | β | β | β |
| Current ratio | 2.4x | 4.2x | 6.7x | 7.9x | 10.1x | 5.6x | 6.9x | 4.4x | 3.4x | 2.9x |
| Quick ratio | 2.3x | 4.1x | 6.5x | 7.8x | 10.0x | 5.5x | 6.8x | 4.3x | 3.3x | 2.9x |
| Capital allocation | ||||||||||
| Capex / revenue | 0.2% | 0.3% | 0.1% | 0.4% | 0.4% | 0.1% | 0.1% | 0.0% | 0.3% | 0.0% |
| Stock comp / revenue | 8.7% | 8.4% | 9.5% | 9.6% | 9.5% | 11.7% | 10.6% | 10.2% | 9.1% | 11.1% |
| Payouts / FCF | 0.0% | 0.0% | 20.5% | 22.9% | 6.6% | 0.0% | 0.0% | 0.0% | 8.0% | 122.0% |
| Quality scores | ||||||||||
| Piotroski F-score | 8.0 | 7.0 | 5.0 | 6.0 | 5.0 | 4.0 | 8.0 | 4.0 | 5.0 | 3.0 |
| Altman Z'' | β9.0 | 8.4 | 13.0 | 15.4 | 18.3 | 15.1 | 14.2 | 11.6 | 10.2 | 9.0 |
| Accruals ratio | β17.0% | 47.1% | β15.1% | β11.6% | β9.3% | β11.1% | β3.8% | β3.4% | β7.8% | β5.1% |
Source: SEC EDGAR XBRL filings (CIK 0001088856). Data updated October 14, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
